Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Zdiagnozowany zaawansowany drobnokomórkowy rak płuca (po zmianie z innego typu raka płuca po leczeniu), które nie były leczone na ten typ choroby (możliwy jeden cykl chemioterapii).
- •Wcześniej zdiagnozowany niedrobnokomórkowy rak płuca z mutacją EGFR, leczony lekami typu inhibitorów kinazy tyrozynowej.
- •Zdrowe narządy i dobry ogólny stan zdrowia.
✗ Disqualifies
- •Aktywne lub nieleczone problemy z mózgiem, rdzeniem kręgowym lub oponami mózgowymi.
- •Ryzyko krwawienia lub powstania przetoki (np. z powodu martwicy guza, naciekania naczyń krwionośnych).
- •Inny nowotwór w ciągu ostatnich 3 lat (z wyjątkiem tych o niskim ryzyku).
- •Nawracające lub nieustępujące skutki uboczne wcześniejszego leczenia nowotworowego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
City of Hope National Medical Center
Duarte, United States
City of Hope Lennar Foundation Cancer Center
Irvine, United States
Hope and Healing Clinical Research
Hinsdale, United States
Hope and Healing Clinical Research
New Lenox, United States
Hospital São Lucas da PUCRS
Porto Alegre, Brazil
Peking Union Medical College Hospital
Beijing, China
Fujian Cancer Hospital
Fuzhou, China
Henan Cancer Hospital
Zhengzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Shanghai Chest Hospital
Shanghai, China
Institut Gustave Roussy
Villejuif, France
Centre Léon Bérard
Lyon, France
Queen Mary Hospital
Hong Kong, Hong Kong
Sheba Medical Center
Ramat Gan, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
IRCCS Istituto Nazionale dei Tumori Regina Elena
Roma, Italy
A.O.U. San Luigi Gonzaga
Orbassano, Italy
Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni
Bergamo, Italy
Kansai Medical University Hospital
Hirakata, Japan
National Cancer Center - Tsukiji Campus
Chūō, Japan
Japanese Foundation for Cancer Research
Kotoku, Japan
Osaka International Cancer Institute(OICI)
Osaka, Japan
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Cancer Center (NTUCC)
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.